BlossomHill Therapeutics, Inc. Common Stock (NASDAQ:BLSM) — Market Cap & Net Worth
Market Cap & Net Worth: BlossomHill Therapeutics, Inc. Common Stock (BLSM)
BlossomHill Therapeutics, Inc. Common Stock (NASDAQ:BLSM) has a market capitalization of $508.34 Million ($508.34 Million) as of October 10, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #12236 globally and #3035 in its home market, demonstrating a -5.97% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying BlossomHill Therapeutics, Inc. Common Stock's stock price $17.48 by its total outstanding shares 29081160 (29.08 Million).
BlossomHill Therapeutics, Inc. Common Stock Market Cap History: 2026 to 2026
BlossomHill Therapeutics, Inc. Common Stock's market capitalization history from 2026 to 2026. Data shows growth from $508.34 Million to $508.34 Million (0.00% CAGR). Check BLSM stock price for real-time trading data and today's change.
BlossomHill Therapeutics, Inc. Common Stock Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how BlossomHill Therapeutics, Inc. Common Stock's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Also see BlossomHill Therapeutics, Inc. Common St cash flow conversion for how efficiently the company converts equity into cash flow.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of BLSM by Market Capitalization
Companies near BlossomHill Therapeutics, Inc. Common Stock in the global market cap rankings as of October 10, 2026. See BLSM net asset quality index to understand what proportion of total assets are financed by equity.
Key companies related to BlossomHill Therapeutics, Inc. Common Stock by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #185 globally with a market cap of $129.29 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #366 globally with a market cap of $75.50 Billion USD.
- CSL Ltd (AU:CSL): Ranked #448 globally with a market cap of $63.11 Billion USD ( AU$89.19 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #506 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #185 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $129.29 Billion | $510.08 |
| #366 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $75.50 Billion | $746.54 |
| #448 | CSL Ltd | AU:CSL | $63.11 Billion | AU$183.84 |
| #506 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $225.00 |
BlossomHill Therapeutics, Inc. Common Stock Historical Marketcap From 2026 to 2026
Between 2026 and today, BlossomHill Therapeutics, Inc. Common Stock's market cap moved from $508.34 Million to $ 508.34 Million, with a yearly change of 0.00%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $508.34 Million | -- |
End of Day Market Cap According to Different Sources
On Oct 10th, 2026 the market cap of BlossomHill Therapeutics, Inc. Common Stock was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $508.34 Million USD |
| MoneyControl | $508.34 Million USD |
| MarketWatch | $508.34 Million USD |
| marketcap.company | $508.34 Million USD |
| Reuters | $508.34 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About BlossomHill Therapeutics, Inc. Common Stock
BlossomHill Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops small molecule medicines that address medical needs in cancer treatment. Its pipeline includes BH-30643, an OMNI-EGFR inhibitor in clinical development for advanced EGFR-mutant non-small cell lung cancer (NSCLC), BH-501284, and BH-30236, a macrocyclic CLK (Cdc2-like kinase) inhibitor being evaluated in patients w… Read more